GlassScriptPhysician profile
Timur T Graham
NPI 1497933683
$7,179.35
in general payments reported to CMS, 2019-2025
33 companies · $2,257 in 2025
The $2,257 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $10.08 · 2021: $20.08 · 2022: $292 · 2023: $1,941 · 2024: $2,507 · 2025: $2,257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,705.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,373.17 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $945.13 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $724.13 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.46 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Novartis Pharmaceuticals Corporation | $295.43 | 2023-2024 | |
| Pfizer INC. | $247.83 | 2021-2025 | |
| United Therapeutics Corporation | $243.96 | 2023-2025 | Tyvaso, Tyvaso |
| Mylan Specialty L.P. | $221.51 | 2019-2024 | Yupelri |
| Amgen INC. | $189.55 | 2023-2025 | Tezspire, Tavneos |
| Takeda Pharmaceuticals U.S.A., INC. | $183.60 | 2024-2025 | Glassia |
| Genentech USA, INC. | $136.26 | 2023-2025 | Xolair |
| Actelion Pharmaceuticals US, INC. | $120.73 | 2019-2025 | Opsumit, Opsynvi |
| Inogen, INC. | $117.78 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Regeneron Healthcare Solutions, INC. | $117.30 | 2022-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $115.70 | 2024-2025 | Acthar |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113.11 | 2023-2025 | |
| Verona Pharma, INC. | $95.42 | 2025 | Ohtuvayre |
| Philips North America LLC | $91.67 | 2023-2024 | (Ak6) Vest Therapy |
| Grifols USA, LLC | $90.51 | 2024-2025 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $69.11 | 2023-2025 | Zerbaxa |
| Baxter Healthcare | $48.98 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Sanofi Pasteur INC. | $46.65 | 2023 | |
| Boston Scientific Corporation | $42.82 | 2022-2023 | |
| Covis Pharma Gmbh | $35.02 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.76 | 2024 | Eliquis |
| Liquidia Technologies, INC. | $21.45 | 2025 | Yutrepia |
| Insmed, INC. | $20.39 | 2025 | Arikayce |
| Sunovion Pharmaceuticals INC. | $19.79 | 2019 | |
| Paratek Pharmaceuticals, INC. | $16.81 | 2023 | Nuzyra |
| Pulmonx Corporation | $16.23 | 2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Electromed, INC. | $12.73 | 2023 | Smartvest |
| Jazz Pharmaceuticals INC. | $11.28 | 2019 | |
| Vapotherm INC | $10.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timur Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.